Banco Products (India) Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 4, 2025, 3:45 pm

Competitors of Banco Products (India) Ltd

All Competitor Stocks of Banco Products (India) Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:05 pm

Below is a detailed analysis of the quarterly data for Banco Products (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 970.00 Cr.. The value appears strong and on an upward trend. It has increased from 875.00 Cr. (Mar 2025) to 970.00 Cr., marking an increase of 95.00 Cr..
• For Expenses, as of Jun 2025, the value is 788.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 660.00 Cr. (Mar 2025) to 788.00 Cr., marking an increase of 128.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 182.00 Cr.. The value appears to be declining and may need further review. It has decreased from 214.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 32.00 Cr..
• For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Mar 2025) to 19.00%, marking a decrease of 5.00%.
• For Other Income, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 24.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 12.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 164.00 Cr.. The value appears to be declining and may need further review. It has decreased from 190.00 Cr. (Mar 2025) to 164.00 Cr., marking a decrease of 26.00 Cr..
• For Tax %, as of Jun 2025, the value is 33.00%. The value appears to be increasing, which may not be favorable. It has increased from 19.00% (Mar 2025) to 33.00%, marking an increase of 14.00%.
• For Net Profit, as of Jun 2025, the value is 110.00 Cr.. The value appears to be declining and may need further review. It has decreased from 154.00 Cr. (Mar 2025) to 110.00 Cr., marking a decrease of 44.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 7.66. The value appears to be declining and may need further review. It has decreased from 10.73 (Mar 2025) to 7.66, marking a decrease of 3.07.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:27 pm

Growth

Last Updated: September 5, 2025, 12:30 am

Balance Sheet

Last Updated: September 10, 2025, 1:32 pm

Below is a detailed analysis of the balance sheet data for Banco Products (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2024) to 29.00 Cr., marking an increase of 15.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,274.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,037.00 Cr. (Mar 2024) to 1,274.00 Cr., marking an increase of 237.00 Cr..
• For Borrowings, as of Mar 2025, the value is 573.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 423.00 Cr. (Mar 2024) to 573.00 Cr., marking an increase of 150.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 868.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 508.00 Cr. (Mar 2024) to 868.00 Cr., marking an increase of 360.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,744.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,982.00 Cr. (Mar 2024) to 2,744.00 Cr., marking an increase of 762.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 516.00 Cr.. The value appears strong and on an upward trend. It has increased from 454.00 Cr. (Mar 2024) to 516.00 Cr., marking an increase of 62.00 Cr..
• For CWIP, as of Mar 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2024) to 5.00 Cr., marking a decrease of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 38.00 Cr., marking an increase of 38.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,185.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,518.00 Cr. (Mar 2024) to 2,185.00 Cr., marking an increase of 667.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,744.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,982.00 Cr. (Mar 2024) to 2,744.00 Cr., marking an increase of 762.00 Cr..

Notably, the Reserves (1,274.00 Cr.) exceed the Borrowings (573.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Banco Products (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 27.39. This value is within the healthy range. It has decreased from 37.95 (Mar 24) to 27.39, marking a decrease of 10.56.
• For Diluted EPS (Rs.), as of Mar 25, the value is 27.39. This value is within the healthy range. It has decreased from 37.95 (Mar 24) to 27.39, marking a decrease of 10.56.
• For Cash EPS (Rs.), as of Mar 25, the value is 33.99. This value is within the healthy range. It has decreased from 48.57 (Mar 24) to 33.99, marking a decrease of 14.58.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 91.05. It has decreased from 146.95 (Mar 24) to 91.05, marking a decrease of 55.90.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 91.08. It has decreased from 147.03 (Mar 24) to 91.08, marking a decrease of 55.95.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 224.59. It has decreased from 387.09 (Mar 24) to 224.59, marking a decrease of 162.50.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 45.74. This value is within the healthy range. It has decreased from 64.33 (Mar 24) to 45.74, marking a decrease of 18.59.
• For PBIT / Share (Rs.), as of Mar 25, the value is 39.14. This value is within the healthy range. It has decreased from 53.70 (Mar 24) to 39.14, marking a decrease of 14.56.
• For PBT / Share (Rs.), as of Mar 25, the value is 37.35. This value is within the healthy range. It has decreased from 50.71 (Mar 24) to 37.35, marking a decrease of 13.36.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 27.39. This value is within the healthy range. It has decreased from 37.95 (Mar 24) to 27.39, marking a decrease of 10.56.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 27.39. This value is within the healthy range. It has decreased from 37.95 (Mar 24) to 27.39, marking a decrease of 10.56.
• For PBDIT Margin (%), as of Mar 25, the value is 20.36. This value is within the healthy range. It has increased from 16.61 (Mar 24) to 20.36, marking an increase of 3.75.
• For PBIT Margin (%), as of Mar 25, the value is 17.42. This value is within the healthy range. It has increased from 13.87 (Mar 24) to 17.42, marking an increase of 3.55.
• For PBT Margin (%), as of Mar 25, the value is 16.62. This value is within the healthy range. It has increased from 13.10 (Mar 24) to 16.62, marking an increase of 3.52.
• For Net Profit Margin (%), as of Mar 25, the value is 12.19. This value exceeds the healthy maximum of 10. It has increased from 9.80 (Mar 24) to 12.19, marking an increase of 2.39.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 9.80 (Mar 24) to 12.19, marking an increase of 2.39.
• For Return on Networth / Equity (%), as of Mar 25, the value is 30.08. This value is within the healthy range. It has increased from 25.82 (Mar 24) to 30.08, marking an increase of 4.26.
• For Return on Capital Employeed (%), as of Mar 25, the value is 32.38. This value is within the healthy range. It has increased from 28.32 (Mar 24) to 32.38, marking an increase of 4.06.
• For Return On Assets (%), as of Mar 25, the value is 13.76. This value is within the healthy range. It has increased from 13.38 (Mar 24) to 13.76, marking an increase of 0.38.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.21 (Mar 24) to 0.24, marking an increase of 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.32. It has decreased from 1.42 (Mar 24) to 1.32, marking a decrease of 0.10.
• For Current Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 2.24 (Mar 24) to 1.98, marking a decrease of 0.26.
• For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 0.86 (Mar 24) to 0.74, marking a decrease of 0.12.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.79. This value is below the healthy minimum of 4. It has increased from 1.59 (Mar 24) to 2.79, marking an increase of 1.20.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 40.15. This value is within the healthy range. It has decreased from 89.59 (Mar 24) to 40.15, marking a decrease of 49.44.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 32.36. This value is within the healthy range. It has decreased from 69.99 (Mar 24) to 32.36, marking a decrease of 37.63.
• For Earning Retention Ratio (%), as of Mar 25, the value is 59.85. This value is within the healthy range. It has increased from 10.41 (Mar 24) to 59.85, marking an increase of 49.44.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 67.64. This value is within the healthy range. It has increased from 30.01 (Mar 24) to 67.64, marking an increase of 37.63.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 25.52. This value is within the healthy range. It has increased from 21.54 (Mar 24) to 25.52, marking an increase of 3.98.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 16.29. This value is within the healthy range. It has increased from 13.70 (Mar 24) to 16.29, marking an increase of 2.59.
• For Enterprise Value (Cr.), as of Mar 25, the value is 5,131.35. It has increased from 4,411.67 (Mar 24) to 5,131.35, marking an increase of 719.68.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.60. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 1.60, marking an increase of 0.01.
• For EV / EBITDA (X), as of Mar 25, the value is 7.84. This value is within the healthy range. It has decreased from 9.59 (Mar 24) to 7.84, marking a decrease of 1.75.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.54.
• For Retention Ratios (%), as of Mar 25, the value is 59.84. This value is within the healthy range. It has increased from 10.40 (Mar 24) to 59.84, marking an increase of 49.44.
• For Price / BV (X), as of Mar 25, the value is 3.79. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.79, marking a decrease of 0.26.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.54.
• For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.07, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness